Group 1: Market Overview - The National Medical Insurance Administration is advancing the "going out" strategy for Chinese pharmaceuticals and medical devices, with a focus on building a multi-level support network for international procurement by 2026[1] - In 2025, China is expected to approve 76 innovative drugs, with over 150 transactions amounting to more than $130 billion[1] - By 2024, China's medical device exports are projected to account for 8.17% of the global market, maintaining the fourth position worldwide[1] Group 2: Financial Performance - Revenue for medical device manufacturing companies in China is expected to reach 1.42 trillion yuan in 2025, reflecting a year-on-year growth of 5%[1] - As of October 2025, the number of medical device manufacturers in China reached 33,300, an increase of 576 from the end of 2024[1] - The number of effective invention patents in the medical device sector is projected to reach 50,525 by 2024, a year-on-year increase of 21.63%[1] Group 3: Export and Import Trends - From January to October 2025, the export value of IVD instruments, diagnostic equipment, and dental materials was 30.8 billion yuan, 67.4 billion yuan, and 9.3 billion yuan respectively, with year-on-year growth rates of 11.16%, 9.43%, and 12.15%[1] - IVD reagent imports saw a year-on-year decline of 22.89%, indicating reduced reliance on imports, while high-end diagnostic equipment still shows demand[1] Group 4: Stock Market Performance - The North Exchange's pharmaceutical and biological sector saw a weekly increase of 1.18%, with medical devices rising by 1.83%[2] - 85.71% of pharmaceutical and biological stocks on the North Exchange experienced price increases this week[2]

Market Overview - The Shanghai Composite Index is at 4164.11 points, slightly above the six-month moving average, with a change of -0.03% [1] - The total trading volume of A-shares today is 185.05 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 168 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Nearshore Protein (近岸蛋白) with a deviation rate of 19.69% and a price increase of 19.99% [1] - Erkang Pharmaceutical (尔康制药) with a deviation rate of 17.97% and a price increase of 19.14% [1] - Wanbang Pharmaceutical (万邦医药) with a deviation rate of 12.41% and a price increase of 12.85% [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Bo Wen Technology (博闻科技) with a deviation rate just above the average [1] - Jilin Expressway (吉林高速) and Teda Investment (泰达股份) also show minor deviations [1] Additional Notable Stocks - Other stocks with notable performance include: - Deer Medical (鹿得医疗) with a price increase of 13.63% and a deviation rate of 11.86% [1] - Chuaning Biological (川宁生物) with a price increase of 12.84% and a deviation rate of 10.67% [1] - New Zhi Biological (新芝生物) with a price increase of 14.33% and a deviation rate of 10.66% [1]

Group 1 - The stock price of Lude Medical (920278) closed at 10.2 yuan on January 12, 2026, with an increase of 5.92% and a turnover rate of 21.14%, resulting in a trading volume of 156,500 shares and a transaction amount of 155 million yuan [1] - On January 12, 2026, the net inflow of main funds was 18.02 million yuan, accounting for 11.61% of the total transaction amount, while retail investors had a net outflow of 2.22 million yuan, representing 1.43% of the total transaction amount [1][3] - The company held its 13th meeting of the 4th Board of Directors on January 9, 2026, where it approved the postponement of the "Lude Medical Health Smart Industrial Park" fundraising project without changing the total investment amount or the use of raised funds [1] Group 2 - The "Lude Medical Health Smart Industrial Park" project has been delayed from the original expected completion date of February 7, 2026, to June 30, 2027, due to economic conditions and market demand [2][3] - As of December 31, 2025, the project had accumulated an investment of approximately 85.25 million yuan, with an investment progress of 72.81% [2]

Group 1 - The core point of the article is that Lude Medical (920278) has experienced a stock price increase of 5.92% to 10.2 yuan, with a total market capitalization of 1.78 billion yuan as of January 12, 2026 [1] - The stock opened at 9.81 yuan, reached a high of 10.24 yuan, and a low of 9.54 yuan, with a trading volume of 1.55 billion yuan and a turnover rate of 21.14% [1] - Lude Medical announced a delay in the construction progress of its "Lude Medical Health Smart Industrial Park" project due to economic conditions and market demand, pushing the expected completion date from February 7, 2026, to June 30, 2027 [1] - As of December 31, 2025, the project has utilized 85,249,547.09 yuan of raised funds, achieving an investment progress of 72.81% [1] - The decision regarding the project delay has been approved by the board of directors and relevant committees, with no objections from the sponsoring institution [1]

证券代码：920278 证券简称：鹿得医疗 公告编号：2026-002 江苏鹿得医疗电子股份有限公司部分募投项目延期公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 募集资金基本情况 2020 年 6 月 29 日，江苏鹿得医疗电子股份有限公司发行普通股 17,500,000 股，发行方式为不特定合格投资者公开发行，发行价格为 8.55 元/股，募集资金 总额为 149,625,000.00 元，募集资金净额为 138,770,570.99 元，到账时间为 2020 年 7 月 16 日。 二、 募集资金使用情况 截至 2025 年 12 月 31 日，公司上述发行股份的募集资金使用情况具体如下： | | | | | 募集资金计划 | 累计投入募集 | 投入进度（%） | | --- | --- | --- | --- | --- | --- | --- | | 序 | 募集资金用 | 实施 | | 投资总额（调整 | 资金金额 | （3）=（2）/ | | 号 | 途 | 主体 | | 后） ...

方正证券承销保荐有限责任公司 关于江苏鹿得医疗电子股份有限公司部分募投项目 延期事项的核查意见 方正证券承销保荐有限责任公司(以下简称"方正承销保荐"或"保荐机构") 作为江苏鹿得医疗电子股份有限公司（以下简称"鹿得医疗"或"公司"）向不 特定合格投资者公开发行股票的保荐机构,根据《证券发行上市保荐业务管理办 法》《北京证券交易所上市公司持续监管办法》《北京证券交易所证券发行上市 保荐业务管理细则》《北京证券交易所股票上市规则》等有关规定,对鹿得医疗 部分募投项目延期事项进行了核查,具体情况如下: 一、公开发行募集资金基本情况 公司于2020年6月29日收到中国证券监督管理委员会下发的《关于核准江苏 鹿得医疗电子股份有限公司向不特定合格投资者公开发行股票的批复》(证监许 可[2020]1299号），核准公司向不特定合格投资者公开发行不超过17,500,000股 新股,公司向不特定合格投资者发行新股数17,500,000股,发行价格为人民币8.55 元/股,募集资金总额为人民币149,625,000.00元,扣除相关发行费用后实际募集 资金净额为人民币138,770,570.99元。上述募集资金已到账,由立信会 ...

证券代码：920278 证券简称：鹿得医疗 公告编号：2026-001 江苏鹿得医疗电子股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2026 年 1 月 9 日 2.会议召开地点：南通工厂会议室 3.会议召开方式：现场及电话连线 4.发出董事会会议通知的时间和方式：2025 年 12 月 29 日以书面方式发出 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《公司部分募投项目延期的议案》 1.议案内容： 综合考虑当前募投项目实施进度等因素，公司决定对募投项目"鹿得医疗健 5.会议主持人：董事长项友亮 6.会议列席人员：高级管理人员 7.召开情况合法合规的说明： 会议召集、召开、议案审议程序符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》有关规定 （二）会议出席情况 康智慧产业园"进行延期。项目的延期未改变募投项目的投资总额、实施主体、 投资 ...

Group 1 - The report highlights the launch of "ChatGPT Health" by OpenAI, which integrates health-related conversations and connects to electronic medical records, indicating a significant potential market for AI in healthcare [9][12] - The "Artificial Intelligence + Manufacturing" initiative aims to achieve reliable supply of core AI technologies and maintain a leading position in the industry by 2027, with specific targets including the application of 3-5 general large models in manufacturing and the creation of 100 high-quality industrial datasets [12][14] - The report identifies key sectors such as AI healthcare, AI pharmaceuticals, and AI biomanufacturing as focal points for development, proposing measures like building intelligent drug discovery platforms and smart supply chain management systems [16][12] Group 2 - The North Exchange's biopharmaceutical sector saw a weekly increase of 5.85%, with medical devices rising by 7.81%, indicating strong market performance [23][26] - Among the biopharmaceutical companies, 90.48% experienced stock price increases, with notable performers including BeiYikang (+45.1%) and XinGanjian (+10.46%) [33][34] - As of January 9, 2026, there are 15 companies in the biopharmaceutical sector awaiting approval on the North Exchange, with an average projected revenue of 424 million yuan for 2024 [34][38] Group 3 - The report emphasizes the importance of AI in enhancing drug development efficiency and supply chain management, aiming to reduce costs and time in pharmaceutical processes [16][12] - The global AI healthcare market is projected to reach approximately $26.65 billion in 2024, with a compound annual growth rate (CAGR) of 38.8% expected until 2033 [18][17] - The Chinese AI healthcare industry is expected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting significant growth potential in this sector [18][19]

Group 1 - The report highlights the significant progress in the pharmaceutical and healthcare system reforms during the "14th Five-Year Plan" period, with a focus on grassroots healthcare and urban-rural integration [1][12] - The "15th Five-Year Plan" emphasizes the support for innovative drugs and medical devices, aiming to enhance the healthcare system and promote the development of traditional Chinese medicine [1][17] - The report indicates that the 11th batch of national drug procurement successfully implemented innovative goals, including maintaining clinical stability and quality assurance [1][14] Group 2 - As of December 31, 2025, the total market capitalization of 21 pharmaceutical and biotechnology companies on the North Exchange reached 748.30 billion, reflecting a growth of 45.81% from the beginning of the year [2][20] - The average market capitalization of these companies increased to 35.63 billion, up 38.87% from the previous year [2][21] - The North Exchange's pharmaceutical sector is primarily composed of chemical pharmaceuticals (38.10%), medical devices (28.57%), and biological products (19.05%) [2][31] Group 3 - In 2025, the North Exchange's pharmaceutical and biotechnology sector experienced a year-on-year increase of 37.38%, ranking third among various sectors [3][54] - The report notes that 80.95% of the pharmaceutical companies on the North Exchange saw an increase in their stock prices throughout the year [3][42] - The top-performing companies in terms of stock price growth included JinHao Medical (+174.08%), NuoSiLanDe (+105.64%), and BeiYiKang (+76.39%) [3][45] Group 4 - The report indicates that the North Exchange's pharmaceutical companies had a PE TTM average of 73X by the end of 2025, with a peak of 119X in August [2][34] - The distribution of valuations shows that the North Exchange has a higher proportion of companies with significant losses compared to other exchanges, with 28.57% of companies in the loss category [2][40] - The report highlights that the North Exchange's pharmaceutical sector is characterized by a high concentration of companies in the 100X and above PE TTM range [2][43]

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]